• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Antibiotics: An International Journal >Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus
【24h】

Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus

机译：行业激励和抗生素抗性：抗生素易感性奖励的介绍

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The scarcity of novel antibiotic compounds in a time of increasing resistance rates has begun to ring alarm bells at the highest echelons of government. Large new financial incentives to accelerate antibiotic research and development, such as market entry rewards (MERs), are being considered. However, there is little focus on how to sustain the efficacy of new, promising antibiotics reaching the market. Currently, inappropriate use of antibiotics is commonplace, which has accelerated resistance development. In an attempt to halt this trend, antibiotic stewardship policies are being implemented in many resource-rich settings. Unfortunately, this has not yet had an impact on the amount of antibiotics being prescribed globally. One important hurdle is misalignment of incentives. While governments and health services are incentivized to promote prudent use of this common good, pharmaceutical companies are incentivized to increase volume of sales to maximize profits. This problem must be addressed or else the major efforts going into developing new antibiotics will be in vain. In this paper we outline an approach to realign the incentives of pharmaceutical companies with wider antibiotic conservation efforts by making a staged bonus a component of an MER for antibiotic developers when resistance to their drug remains low over time. This bonus could address the lack of stewardship focus in any innovation-geared incentive.
机译：在耐药率升高的时间内新抗生素化合物的稀缺性已经开始在政府最高梯度的戒指中响起警钟。正在考虑加速抗生素研究和发展的大型新的金融激励，例如市场入学奖励（MERS）。然而，几乎没有侧重于如何维持新的抗生素达到市场的新抗生素的疗效。目前，不适当地使用抗生素是常见的，这具有促进抗性发展。为了停止这种趋势，在许多资源丰富的环境中正在实施抗生素管理策略。不幸的是，这尚未对全球规定的抗生素量产生影响。一个重要的障碍是对激励措施的不对准。虽然各国政府和卫生服务被激励促进审慎使用这种共同的良好，但制药公司被激励增加销售额以最大化利润。必须解决这个问题，否则开发新抗生素的主要努力将是徒劳的。在本文中，我们概述了一种方法来重建制药公司的激励，通过制作抗生素开发人员的分阶段奖励，当抗生素显影剂​​随着时间的推移仍然低位而进行分阶段的奖金。这笔奖金可以解决任何创新驾驶激励的缺乏管理焦点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号